ClinicalTrials.gg
CompletedNCT01159028Updated May 28, 2020

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

A Phase 1 interventional study of BP1001 and BP1001 in combination with LDAC in Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome, sponsored by Bio-Path Holdings, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-05-28.

Sponsored by Bio-Path Holdings, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
554th of 1,908
60 · median 35
Started
2010
with 69 others
Phase 1
772 of 2,138
127 open now
Registered
745th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 554th largest by planned enrollment of the 1,908 interventional ones that give a count, is one of 70 that started in 2010, is one of 772 in phase 1, and was the 745th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

The first goal of this clinical research study is to find the highest safe dose of BP1001, a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS), for patients with Philadelphia Chromosome positive CML, AML, ALL and MDS. The response of the leukemia to this treatment will also be studied. The second goal of this clinical research study is to evaluate the safety and toxicity of the combination of BP1001 and concurrent low-dose ara-C (LDAC) in patients with AML.

Read the detailed description

The Philadelphia Chromosome is an unusual genetic trait found in 90-95% of patients with CML and approximately 20-25% of patients with ALL. The protein created by this unusual trait causes normal cells within the body to become cancer cells, and then causes these cells to grow and divide at a rapid rate. Researchers think that the protein "Growth Factor Receptor Bound Protein-2 (Grb-2)" plays an important role in the rapid growth of leukemic cells. The study drug (BP1001) may be able to inhibit the cells from making Grb-2. Researchers hope that without this protein, the leukemia cells will die.

Up to 60 patients are expected to be enrolled on this study.

Part A: Dose escalation: Each cohort will receive BP1001 at a dose higher than the previous group.

Part B: Dose-expansion Cohorts: Subjects with relapsed or refractory AML will receive escalating doses of BP1001 concurrently with fixed low-dose ara-C (LDAC)

The study drug is an antisense molecule complementary to the messenger RNA (mRNA) code for the cell's expression of the protein Grb-2. The study drug is incorporated into lipid (fat) particles known as liposomes. This incorporation process is part of the manufacturing process and is done before the study drug is administered. The liposomes (which carry the study drug) will be administered intravenously twice a week for 28 days. Subjects enrolled in Part B of the study will receive study drug twice a week for 28 days concurrently with low dose ara-C, self administered twice daily for 10 consecutive days.

03

Conditions studied

  • Recurrent Adult Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Myelodysplastic Syndrome
  • Ph1 Positive CML

Keywords

  • Liposomal Grb-2 treatment of CML, AML, CLL, MDS
  • Liposomal Grb-2 with LDAC for AML
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients 18 years of age or older
  2. A diagnosis of or relapsed AML, or Ph+ CML (in chronic, accelerated or blast phase, or acute lymphoblastic leukemia, or myelodysplastic syndrome.

    One of the following parameters is required to meet criteria for accelerated phase CML:

    • Blasts in Peripheral Blood or Bone Marrow ≥15%
    • Promyelocytes and Blasts in Peripheral Blood or Bone Marrow ≥30%
    • PB or BM basophils ≥20%
    • Thrombocytopenia \<100 x 103/ml, not resulting from therapy

    Blast phase is defined as ≥30% blasts in peripheral blood or bone marrow, or presence of extramedullary disease, except for liver or spleen.

  3. Patients with CML must have demonstrated resistance and/or intolerance to therapy with at least 2 tyrosine kinase inhibitors (TKI)
  4. Patients with AML and ALL should have received at least 1 prior treatment regimen and either failed to achieve response or relapsed on treatment
  5. Patients with MDS should have failed prior therapy with a hypomethylating agent or, if associated with a 5q- chromosomal abnormality, lenalidomide. NOTE: Patients with 5q- unable to receive or intolerant to lenalidomide are also eligible.
  6. Have clinically adequate hepatic and renal functions as defined by:

    • \<2x
    • Serum creatinine concentration \<2x ULN
    • Serum \<2x ULN
  7. Patients must sign an
  8. Women of childbearing age must have a negative serum or urine pregnancy test prior to the initiation of study drug.
  9. Barrier precautions are to be used throughout the trial by all study participants of child bearing potential.
  10. Have not received anti-cancer therapy for at least 2 weeks prior to study entry, with the exception of low dose ara-C (LDAC) given as subcutaneous injections (no less than 15 days prior), hydroxyurea or anagrelide (no less than 24 hours prior), TKI (no less than 5 days prior), and interferon (no less than 2 weeks prior)
  11. Have an Performance of 0-2
  12. Have a life-expectancy ≥3 months

Exclusion criteria

Exclusion Criteria

  1. Serious intercurrent medical illnesses which would interfere with the ability of the patient to carry out the treatment program
  2. Pregnant or breastfeeding women
  3. Patients who have uncontrolled active infection
  4. Patients who have received another product within the longer of 14 days or 5 half-lives of the previous product
  5. Any history of adverse reaction or to LDAC

Part B: BP1001 with Concurrent LDAC Dose-Expansion Cohorts

Enrollment in the dose-expansion cohorts (DEC) will be limited to only those patients with a diagnosis of or relapsed AML(except acute promyelocytic leukemia) or those who are refractory to at least 1 prior therapy regimen and no more than 1 prior salvage regimen.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    BP1001

    Subjects are treated with open-label study drug (BP1001) in a dose-escalation model.

    Drug: BP1001

  • Experimental
    BP1001 in combination with LDAC

    AML subjects are treated with open-label escalating study drug (BP1001) in combination with low dose ara-C (LDAC)

    Drug: BP1001 in combination with LDAC

Interventions

  • DrugPrexigebersenStudies of PrexigebersenPrexigebersen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.

    Also known as: Liposomal Grb-2, L-Grb-2, BP-100-1.01

  • DrugBP1001 in combination with LDAC

    Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.

    Also known as: Liposomal Grb-2, L-Grb-2, BP-100-1.01, low dose ara-C

06

What researchers measure

Primary outcomes

  1. Safety of BP1001

    Evaluate toxicity, tolerance, and MTD of escalating doses of BP1001

    Time frame: 30 days

  2. Safety of BP1001 in combination with LDAC

    Evaluate safety and toxicity of the combination of BP1001 and concurrent LDAC using non-hematologic and hematologic measures per NCI CTCAE criteria.

    Time frame: 30 days

Secondary outcomes

  1. Optimal biologically active dose

    Determine the optimal biologically active dose of BP1001 defined as a 50% reduction in Grb-2 expression in circulating leukemia cells

    Time frame: 30 days

  2. In vivo pharmacokinetics

    Evaluate the in vivo PK of BP1001 in all subjects using plasma and urine to compute half life and elimination

    Time frame: 30 days

  3. Correlate PK data with historical experience

    Correlate the in vivo PK data with historical experience to demonstrate the liposomal delivery performs as expected for all subjects by comparing PK data (half life and elimination) obtained from each subject with historical experience

    Time frame: 30 days

07

Study locations

1 site
  • M. D. Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Publications

  • Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr;5(4):e136-e146. doi: 10.1016/S2352-3026(18)30021-8. Epub 2018 Mar 14. PubMed 29550383 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2010
First posted
Jul 9, 2010
Start
Jun 2010
Primary completionActual
Mar 30, 2017
CompletionActual
Mar 30, 2017
Last update
May 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01159028
Lead sponsor
Bio-Path Holdings, Inc.
Responsible party
Sponsor
First posted
Jul 9, 2010
Start date
Jun 2010
Primary completion
Mar 30, 2017
Completion
Mar 30, 2017
Last update
May 28, 2020

Study contacts

Jorge Cortes, MD
study chair · M.D. Anderson Cancer Center
Maro Ohanian, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prexigebersen

Start the discussion